BioNotebook
This article was originally published in Scrip
Executive Summary
Transcept Pharmaceuticals schedules special shareholder meeting; Delcath Systems cuts 33% of staff; Isis Pharmaceuticals earns $7m from GlaxoSmithKline; Ligand Pharmaceuticals will start Phase I diabetes study; and Oncothyreon reports Phase I ONT-380 data.